Currenc Group, Inc. (CURR)
USD 1.56
(3.31%)
USD 1.56
(3.31%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.9 Million USD | 71.45% |
| 2022 | -5.53 Million USD | 40.32% |
| 2021 | 5.39 Million USD | 48.16% |
| 2020 | -21.52 Million USD | -79.74% |
| 2019 | -13.46 Million USD | -70.7% |
| 2018 | -7.27 Million USD | 1.85% |
| 2017 | -7.14 Million USD | -85.15% |
| 2016 | -3.85 Million USD | -203.45% |
| 2015 | -1.27 Million USD | -112.55% |
| 2014 | -598.48 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -715 Thousand USD | 119.98% |
| 2024 Q1 | -234.14 Thousand USD | -216.42% |
| 2023 Q2 | -1.78 Million USD | -12.81% |
| 2023 Q4 | 3.25 Million USD | 246.18% |
| 2023 FY | - USD | 71.45% |
| 2023 Q1 | -1.58 Million USD | 16.71% |
| 2023 Q3 | -2.22 Million USD | -24.38% |
| 2022 FY | - USD | 40.32% |
| 2022 Q1 | -2.07 Million USD | 42.93% |
| 2022 Q4 | -1.9 Million USD | 18.47% |
| 2022 Q3 | -2.33 Million USD | -20.81% |
| 2022 Q2 | -1.93 Million USD | 6.89% |
| 2021 FY | - USD | 48.16% |
| 2021 Q4 | -3.63 Million USD | -39.52% |
| 2021 Q1 | -3.44 Million USD | 74.09% |
| 2021 Q2 | -1.47 Million USD | 57.06% |
| 2021 Q3 | -2.6 Million USD | -76.44% |
| 2020 Q2 | -2.95 Million USD | -11.49% |
| 2020 FY | - USD | -79.74% |
| 2020 Q1 | -2.65 Million USD | 11.09% |
| 2020 Q4 | -13.27 Million USD | -403.8% |
| 2020 Q3 | -2.63 Million USD | 10.95% |
| 2019 Q3 | -2.39 Million USD | 35.52% |
| 2019 Q4 | -2.98 Million USD | -24.73% |
| 2019 FY | - USD | -70.7% |
| 2019 Q1 | -2.88 Million USD | -426.02% |
| 2019 Q2 | -3.71 Million USD | -28.66% |
| 2018 Q3 | -2.71 Million USD | -18.58% |
| 2018 Q2 | -2.28 Million USD | -56.24% |
| 2018 FY | - USD | 1.85% |
| 2018 Q4 | -548.42 Thousand USD | 79.79% |
| 2018 Q1 | -1.46 Million USD | -96.57% |
| 2017 Q3 | -1.48 Million USD | 36.89% |
| 2017 FY | - USD | -85.15% |
| 2017 Q1 | -2.56 Million USD | -33.96% |
| 2017 Q4 | -745.01 Thousand USD | 49.75% |
| 2017 Q2 | -2.34 Million USD | 8.59% |
| 2016 Q3 | -8352.00 USD | 18.6% |
| 2016 Q4 | -1.91 Million USD | -22869.68% |
| 2016 Q1 | -468.00 USD | 93.98% |
| 2016 Q2 | -10.26 Thousand USD | -2092.52% |
| 2016 FY | - USD | -203.45% |
| 2015 Q2 | 464.00 USD | 0.0% |
| 2015 Q4 | -7770.00 USD | -464.68% |
| 2015 Q3 | -1376.00 USD | -396.55% |
| 2015 FY | - USD | -112.55% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 98.804% |
| PainReform Ltd. | -9.56 Million USD | 80.138% |
| Alvotech | -484.86 Million USD | 99.608% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 100.616% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 101.739% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 260.793% |
| Journey Medical Corporation | 1.92 Million USD | 198.937% |
| Dynavax Technologies Corporation | 9.66 Million USD | 119.662% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 98.734% |
| Bright Green Corporation | - USD | Infinity% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 101.167% |
| Embecta Corp. | 245.4 Million USD | 100.774% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 50.304% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 50.304% |
| SCYNEXIS, Inc. | 73.47 Million USD | 102.587% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 54.876% |
| Silver Spike Investment Corp. | 7.34 Million USD | 125.893% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 19.159% |
| Alpha Teknova, Inc. | -25.53 Million USD | 92.558% |
| Safety Shot Inc | -12.18 Million USD | 84.403% |
| Procaps Group, S.A. | 104.02 Million USD | 101.827% |
| Cosmos Health Inc. | -17.06 Million USD | 88.861% |
| Theratechnologies Inc. | -10.31 Million USD | 81.571% |
| Harrow Health, Inc. | 9.72 Million USD | 119.547% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 57.998% |
| Biofrontera Inc. | -18.45 Million USD | 89.7% |
| DURECT Corporation | -24.68 Million USD | 92.3% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 101.934% |
| Cronos Group Inc. | -72.14 Million USD | 97.366% |
| OptiNose, Inc. | -15.55 Million USD | 87.78% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.795% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 94.733% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 107.236% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 105.275% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 51.545% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -167.366% |
| Radius Health, Inc. | 38.31 Million USD | 104.961% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 40.885% |
| ProPhase Labs, Inc. | -14.82 Million USD | 87.182% |
| Phibro Animal Health Corporation | 84.6 Million USD | 102.246% |
| Procaps Group S.A. | 104.02 Million USD | 101.827% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 77.377% |
| Viatris Inc. | 3.51 Billion USD | 100.054% |
| Rockwell Medical, Inc. | -4.69 Million USD | 59.511% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -87.804% |
| SIGA Technologies, Inc. | 84.15 Million USD | 102.258% |
| Tilray Brands, Inc. | -72.84 Million USD | 97.391% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 334.061% |
| Shineco, Inc. | -26.55 Million USD | 92.843% |
| PetIQ, Inc. | 81.48 Million USD | 102.332% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 47.464% |
| Incannex Healthcare Limited | -18.5 Million USD | 89.729% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.457% |
| Alimera Sciences, Inc. | 7.27 Million USD | 126.121% |
| Assertio Holdings, Inc. | -222.44 Million USD | 99.146% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 52.374% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 88.69% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 90.512% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 98.726% |
| Hempacco Co., Inc. | -12.77 Million USD | 85.121% |
| Talphera, Inc. | -9.84 Million USD | 80.689% |
| Alvotech | -484.86 Million USD | 99.608% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 102.452% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.387% |
| Kamada Ltd. | 21.53 Million USD | 108.826% |
| Indivior PLC | 66 Million USD | 102.88% |
| Evoke Pharma, Inc. | -7.29 Million USD | 73.937% |
| Flora Growth Corp. | -45.87 Million USD | 95.857% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 90.512% |
| Evolus, Inc. | -41.81 Million USD | 95.454% |
| HUTCHMED (China) Limited | 25.52 Million USD | 107.445% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 100.787% |
| Akanda Corp. | -27.73 Million USD | 93.148% |